Triptorelin: clinical trials recruiting now
6
Recruiting trials
15
Conditions studied
46
US states with sites
7
Countries
FDA drug label
- FDA-approved
- Yes. Triptorelin appears in the FDA drug-label database. Marketed as TRIPTODUR.
FDA-approved use
TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). TRIPTODUR is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years and older with central precocious puberty. ( 1 )
Phase breakdown
Phase 2 3
Phase 3 2
Not applicable 1
Conditions being studied
Recruiting trials involving Triptorelin
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
- Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
- Evaluation of Clinical Outcomes of Chemotherapy or Androgen-receptor Targeting Agent (Alone or Combined) or Radiotherapy on Primary Tumor in Addition to Androgen Deprivation Therapy in HOrmone-Sensitive Metastatic Prostate Cancer Patients
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Common questions
Is Triptorelin FDA-approved?
Yes, marketed as TRIPTODUR.
How many recruiting trials involve Triptorelin?
6 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.